Mortality has taken center stage in the life insurance industry since the outbreak of the COVID-19 pandemic in 2020. Despite expectations of a rebound, death rates have remained higher than projected, driven not only by lingering COVID-19 impacts but also by rising cases of heart disease, diabetes, liver disease, and drug overdoses.
As one of the world’s leading reinsurers, Swiss Re continues to conduct in-depth research into mortality trends. In its most recent study released in September 2025, the company highlighted the potential of GLP-1 weight-loss drugs to transform public health. Under its most optimistic projection, Swiss Re estimates these drugs could reduce cumulative all-cause mortality in the U.S. by 6.4% over the next 20 years.
During the LIMRA 2025 Annual Conference in Orlando, Florida, Neil Sprackling, President of Swiss Re’s U.S. Life & Health division, sat down with InsuranceNewsNet Senior Editor John Hilton to discuss the shifting landscape of mortality and health trends post-pandemic.
With over 40 years of experience in the reinsurance sector, Sprackling joined Swiss Re in 1997 and has played a vital role in shaping the company’s strategic direction. Before taking on his current leadership role in the U.S., he headed Swiss Re’s Life & Health operations in Australia and New Zealand.
Sprackling has been a driving force behind several of Swiss Re’s global initiatives, including efforts to address the protection gap — the widespread issue of underinsurance among individuals and families. His continued focus remains on innovation, longevity research, and developing solutions that help insurers better manage evolving mortality risks.
Burial Senior Insurance provides information and services related to burial insurance for senior citizens, including policy options and end-of-life support services.
Copyright © Burial Senior Insurance 2025. All Right Reserved.
